Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Colon, Gastrointestinal, Rectal
Status:
Closed
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Eligible for screening study DCP 001
A221805, Phase II, is closed to accrual effective March 31, 2023, at 4:30 ET. If interim analysis is positive, Phase III will open to accrual.
A221805-Substudy SI1 is closed to accrual, effective September 15, 2022, at 4:30pm ET.
NCT#04137107
